Interventions of Interest
- iptacopan (Novartis)
- danicopan (AstraZeneca)
For questions please contact Becca Piltch, Program Manager, at bpiltch@icer.org.
View the Key Stakeholder List.
Paroxysmal Nocturnal Hemoglobinuria
An assessment of iptacopan, crovalimab, and danicopan
Public Meeting
February 2024
Assessment Status
Open
Upcoming Milestone
Model Analysis PlanView
Main Review
February 16, 2024
CTAF
The CTAF’s 2024 public meeting on iptacopan, crovalimab, and danicopan.
Related Assessments & Policy Papers.
Amyloidosis
Aug 2018
10/18/2023
Model Analysis Plan
12/05/2023 - 01/09/2024
Public Comments on Draft Evidence Report
02/01/2024
Evidence Report
02/16/2024
Evidence Presentation
03/14/2024
Public Comments
Closed